CapsoVision (NASDAQ:CV) Shares Gap Down – What’s Next?

CapsoVision, Inc. (NASDAQ:CV)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $11.80, but opened at $10.78. CapsoVision shares last traded at $12.38, with a volume of 1,797,496 shares trading hands.

Analyst Ratings Changes

Several research firms recently commented on CV. Zacks Research raised shares of CapsoVision to a “hold” rating in a report on Wednesday, November 5th. Roth Capital set a $7.00 price objective on shares of CapsoVision in a research note on Tuesday, November 4th. Benchmark reiterated a “speculative buy” rating on shares of CapsoVision in a report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (e)” rating on shares of CapsoVision in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $6.00.

CapsoVision Stock Performance

The company’s fifty day moving average price is $5.35.

CapsoVision (NASDAQ:CV) last released its earnings results on Thursday, November 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The firm had revenue of $3.54 million during the quarter.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in CapsoVision stock. New York State Common Retirement Fund bought a new position in CapsoVision, Inc. (NASDAQ:CV) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 7,114 shares of the company’s stock, valued at approximately $34,000.

CapsoVision Company Profile

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn’s disease.